Sign In
Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
APLT.US
id: 1432

Applied Therapeutics ($APLT) Investor Settlement

Eligible claimants can submit their claims for compensation.
$15,000,000
Cash Settlement
S.D. New York
Court
1:24-cv-09715
Case number
01/03/2024
Class period Start
12/02/2024
Class period End
04/08/2026
Claim deadline
Applied Therapeutics ($APLT) has reached a settlement with investors over claims that it misled them about its lead drug candidate by hiding dosing errors and missing trial data, which ultimately led to a failed FDA review.
  • $APLT investors filed a lawsuit against Applied Therapeutics for misleading them about clinical trial data and the regulatory approval process for its lead drug.
  • On November 27, 2024, Applied Therapeutics revealed that the FDA had issued a Complete Response Letter. Following this news, $APLT stock dropped over 80%.
  • $APLT investors can join this case to be notified about potential recovery.
Case Details:

Between January 3, 2024, and December 2, 2024, Applied Therapeutics made several optimistic statements about the clinical trial data and regulatory progress for Govorestat, its drug candidate for the treatment of galactosemia.
On February 15, 2024, the company announced positive results from its Phase III trial, noting significant improvements in patient outcomes and key biomarkers.
However, on November 27, 2024, the FDA issued a Complete Response Letter, pointing out serious deficiencies in the New Drug Application for Govorestat, including incomplete data and protocol inconsistencies.
On December 2, 2024, Applied Therapeutics received a warning letter from the FDA for not adequately addressing past trial issues. This raised concerns about the gap between the company’s public claims and the reality of its clinical data and regulatory compliance.
Following these announcements, $APLT plummeted by over 80%.
Based on these events, $APLT investors filed a lawsuit against Applied Therapeutics, claiming the company:
  • It misled investors about the quality of its clinical trial data and regulatory readiness.
  • It failed to disclose deficiencies in its clinical practices, including trial data capture and protocol errors.
Investors believe Applied Therapeutics misrepresented its clinical trial results and regulatory progress for Govorestat.
Case Type
US Securities Class Action
Case Status
Accepting Claims
Alleged Offence
Mismanagement, 
Misleading Statements
Suspected Party
Directors, 
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.48
Filing date
12/17/2024
Lead Plaintiff Deadline
02/18/2025
Plaintiffs
Martin Dietrich
Attorneys
Levi & Korsinsky, LLP
Defendants
Shoshana Shendelman; Riccardo Perfetti
Administrator
Angeion
Court hearing date
03/19/2026
Exclusion deadline
02/26/2026
Objection deadline
02/26/2026
Trades matching type
FIFO

Frequently Asked Questions

Who is eligible for this settlement?
Do I have to sell securities to be eligible?
How long does the payout process take?
How much will my payment be?
How to get your payout?
What is 11th.com?

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.